November 14, 2017 / 12:26 PM / a year ago

Loxo Oncology to develop, commercialize cancer drugs with Bayer

Nov 14 (Reuters) - U.S. drug developer Loxo Oncology Inc on Tuesday announced a deal with Bayer AG to develop and commercialize two of its cancer therapies and said it would receive $400 million upfront.

Loxo is also eligible to receive milestone payments once the drugs, LOXO-195 and larotrectinib, are approved and sold.

Bayer and Loxo will jointly develop the drugs and evenly split development costs. (Reporting by Tamara Mathias in Bengaluru; Editing by Sai Sachin Ravikumar)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below